GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Now Rated “Hold” by Wall Street Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus rating of “Hold” from the thirteen brokerages that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $4.23.

A number of research firms have recently commented on GDRX. Wells Fargo & Company raised their price target on GoodRx from $3.50 to $5.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Citigroup upped their target price on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Barclays upped their price objective on shares of GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Thursday, August 20th. Finally, Leerink Partners set a $5.00 price target on shares of GoodRx in a report on Thursday, August 6th.

Insider Activity

In related news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 2,760,995 shares of company stock worth $9,673,207 in the last quarter. Company insiders own 5.87% of the company’s stock.

Institutional Investors Weigh In On GoodRx

A number of hedge funds have recently modified their holdings of GDRX. Essential Partners LLC boosted its holdings in GoodRx by 375.4% in the first quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after purchasing an additional 11,295 shares during the period. SG Americas Securities LLC acquired a new position in shares of GoodRx during the first quarter valued at $29,000. Headlands Technologies LLC acquired a new stake in shares of GoodRx in the second quarter valued at $30,000. Krilogy Financial LLC acquired a new position in GoodRx in the 1st quarter worth approximately $33,000. Finally, Amundi acquired a new position in GoodRx in the 1st quarter worth about $37,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Price Performance

Shares of GoodRx stock opened at $3.49 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 87.27, a P/E/G ratio of 1.74 and a beta of 1.66. GoodRx has a 52-week low of $1.77 and a 52-week high of $3.89. The stock has a 50-day simple moving average of $3.43 and a 200-day simple moving average of $2.82.

GoodRx (NASDAQ:GDRX) last released its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%. The company’s revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.09 EPS. On average, equities research analysts expect that GoodRx will post 0.16 earnings per share for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc operates a digital healthcare platform that helps consumers find and access lower prices for prescription medications. Through its website and mobile applications, GoodRx allows users to compare prices at participating pharmacies, obtain prescription discount coupons and identify potential savings on commonly prescribed drugs. The company’s services are generally available at pharmacies across the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as healthcare-related content and tools designed to help consumers understand medications and treatment options.